Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q ...
The Club and leading global sports investor form long-term partnership to support continued growth under CEO Miguel Ángel Gil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback